|
Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED. |
|
|
|
Consulting or Advisory Role - MSD |
|
|
No Relationships to Disclose |
|
|
Employment - Constellation Pharmaceuticals (I); Flagship VL59 (I) |
Stock and Other Ownership Interests - Constellation Pharmaceuticals (I) |
|
|
Leadership - PFS Genomics |
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune |
|
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas |
Research Funding - Zenith Epigenetics |
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Janssen; Janssen (I) |
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems |
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate. |
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems |
Other Relationship - Institute of Cancer Research |
|
|
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics |
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures |
Speakers' Bureau - Illumina |
Research Funding - Bristol-Myers Squibb; Novartis |
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Decipher Biosciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |
|
|
Employment - Decipher Biosciences; GenomeDx |
Leadership - Decipher Biosciences; GenomeDx |
Stock and Other Ownership Interests - Decipher Biosciences; GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Employment - AIQ Solutions |
Leadership - AIQ Solutions |
Stock and Other Ownership Interests - AIQ Solutions |
Consulting or Advisory Role - Exelixis; Janssen; Novartis; Tricon Pharmaceuticals |
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst) |
|
|
Stock and Other Ownership Interests - Leuchemix |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |